Received Dec 29, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| MEN | MENINGOCOCCAL (NO BRAND NAME) | UNKNOWN MANUFACTURER | UNK | — | — |
patient was administered MenQuadfi to the left deltoid, this dose was an extra, unneeded dose with no reported adverse event; Initial information received on 22-Dec-2025 regarding an unsolicited valid non-serious case received from a other health professional. This case involves a 17 years old female patient who received Meningococcal A-C-Y-W135 (T Conj) Vaccine [Menquadfi] to the left deltoid, this dose was an extra, unneeded dose with no reported adverse event. The patient's past medical history, medical treatment(s) and family history were not provided. The patient's past vaccination(s) included Menactra on 02-Dec-2019. On 04-Oct-2024, the patient received an unknown dose of suspect Meningococcal A-C-Y-W135 (T Conj) Vaccine, Solution for injection (unknown strength and expiry date) lot number not reported in unknown administration site for immunisation. On 13-Aug-2025 she also received an extra unneeded 0.5ml dose of Meningococcal A-C-Y-W135 (T Conj) Vaccine, Solution for injection (unknown strength) expiry date 31-Jul-2028 and Lot U8508AA via unknown route in the left deltoid for immunisation with no reported adverse event (extra dose administered) (Latency Same day). Action taken was not applicable. This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in the Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.